*

Hitt og þetta 23. apríl 2007

Holding(s) in Company

TR-1(i): NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii): Sinclair Pharma Plc 2. Reason for the notification (please place an X inside the appropriate bracket/s): An acquisition or disposal of voting rights: ( X ) An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: ( ) An event changing the breakdown of voting rights: ( ) Other (please specify) : ( ) Revised due to DTR rules - see Section 13 3. Full name of person(s) subject to the notification obligation (iii): Fidelity International Limited (FIL) 4. Full name of shareholder(s) (if different from 3.) (iv): 88,175 State Str Bk and Tr Co LNDN (FPM) 133,954 State Str Bk and Tr Co LNDN (FIL) 322,214 Northern Trust London (FPM) 233,000 JP Morgan Bournemouth (FPM) 2,506,738 JP Morgan Bournemouth (FISL) 317,264 JP Morgan Bournemouth (FIL) 272,661 Brown Brothers Harriman and Co (FIJ) 5,277,005 Brown Bros Harriman Ltd Lux (FIL) 182,376 Bank of New York Brussels (FPM) 5. Date of the transaction (and date on which the threshold is crossed or reached if different) (v): 12 April 2007 6. Date on which issuer notified: 16 April 2007 7. Threshold(s) that is/are crossed or reached: 10% 8. Notified details: ....... A: Voting rights attached to shares Class/type of shares if possible Situation previous to the Triggering using the ISIN CODE transaction (vi) Number of shares Number of voting Rights (viii) 9,352,556 9,352,556 Resulting situation after the triggering transaction (vii) Class/type of shares if Number of Number of voting % of voting rights possible using the ISIN shares rights (ix) CODE Direct Direct Indirect Direct Indirect (x) (xi) ISIN 9,333,387 9.99% GB0033856740 B: Financial Instruments Resulting situation after the triggering transaction (xii) Type of Expiration Exercise/Conversion Number of voting % of financial Date (xiii) Period/ Date (xiv) rights that may be voting instrument acquired if the rights instrument is exercised/ converted. Total (A+B) Number of voting rights % of voting rights 9,333,387 9.99% 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv): See attached schedule Proxy Voting: 10. Name of the proxy holder: Fidelity International Limited (FIL) 11. Number of voting rights proxy holder will cease to hold: 19,169 12. Date on which proxy holder will acquire to hold voting rights: 12 April 2007 13. Additional information: 14. Contact name: Teresa Garry, Fidelity Alan Olby (Company Secretary) / Zoe McDougall (Communications), Sinclair Pharma plc 15. Contact telephone number: fil-regulatoryreporting@uk.fid-intl.com investorrelations@sinclairpharma.com Annex to Notification Of Major Interests In Shares (xvi) A: Identity of the person or legal entity subject to the notification obligation Full name (including legal form for legal entities): Fidelity International Limited (FIL) Contact address (registered office for legal entities): Pembroke Hall, 42 Crow Lane, Pembroke, HM19 Bermuda Phone number: 01737 837092 Other useful information (at least legal representative for legal persons): Company Secretary B: Identity of the notifier, if applicable (xvii) Full name: Fidelity Investments International Contact address: Windmill Court XTW2B, Millfield Lane, Lower Kingswood, Tadworth, Surrey KT20 6RB Phone number: 01737 837092 Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation): Authorised to make this filing under power of attorney C: Additional information : Notes to the Forms (i) This form is to be sent to the issuer or underlying issuer and to be filed with the competent authority. (ii) Either the full name of the legal entity or another method for identifying the issuer or underlying issuer, provided it is reliable and accurate. (iii) This should be the full name of (a) the shareholder; (b) the person acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h); (c) all the parties to the agreement referred to in DTR5.2.1 (a), or (d) the direct or indirect holder of financial instruments entitled to acquire shares already issued to which voting rights are attached, as appropriate. In relation to the transactions referred to in points DTR5.2.1 (b) to (h), the following list is provided as indication of the persons who should be mentioned: - in the circumstances foreseen in DTR5.2.1 (b), the person that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights; - in the circumstances foreseen in DTR 5.2.1 (c), the person holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and person lodging the collateral under these conditions; - in the circumstances foreseen in DTR5.2.1(d), the person who has a life interest in shares if that person is entitled to exercise the voting rights attached to the shares and the person who is disposing of the voting rights when the life interest is created; - in the circumstances foreseen in DTR5.2.1 (e), the parent undertaking and, provided it has a notification duty at an individual level under DTR 5.1, under DTR5.2.1 (a) to (d) or under a combination of any of those situations, the controlled undertaking; - in the circumstances foreseen in DTR5.2.1 (f), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion; - in the circumstances foreseen in DTR5.2.1 (g), the person that controls the voting rights; - in the circumstances foreseen in DTR5.2.1 (h), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion. (iv) Applicable in the cases provided for in DTR 5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to in DTR5.2. (v) The date of the transaction should normally be, in the case of an on exchange transaction, the date on which the matching of orders occurs; in the case of an off exchange transaction, date of the entering into an agreement. The date on which threshold is crossed should normally be the date on which the acquisition, disposal or possibility to exercise voting rights takes effect (see DTR 5.1.1R (3)). For passive crossings, the date when the corporate event took effect. (vi) Please refer to the situation disclosed in the previous notification, In case the situation previous to the triggering transaction was below 3%, please state 'below 3%'. (vii) If the holding has fallen below the minimum threshold , the notifying party should not be obliged to disclose the extent of the holding, only that the new holding is less than 3%. For the case provided for in DTR5.2.1(a), there should be no disclosure of individual holdings per party to the agreement unless a party individually crosses or reaches an Article 9 threshold. This applies upon entering into, introducing changes to or terminating an agreement. (viii) Direct and indirect (ix) In case of combined holdings of shares with voting rights attached 'direct holding' and voting rights 'indirect holdings', please split the voting rights number and percentage into the direct and indirect columns-if there is no combined holdings, please leave the relevant box blank. (x) Voting rights to shares in respect of which the notifying party is a direct shareholder (DTR 5.1) (xi) Voting rights held by the notifying party as an indirect shareholder (DTR 5.2.1) (xii) If the holding has fallen below the minimum threshold, the notifying party should not be obliged to disclose the extent of the holding, only that the new holding is below 3%. (xiii) date of maturity / expiration of the finical instrument i.e. the date when the right to acquire shares ends. (xiv) If the financial instrument has such a period-please specify the period- for example once every three months starting from the (date) (xv) The notification should include the name(s) of the controlled undertakings through which the voting rights are held. The notification should also include the amount of voting rights and the percentage held by each controlled undertaking, insofar as individually the controlled undertaking holds 5% or more, and insofar as the notification by the parent undertaking is intended to cover the notification obligations of the controlled undertaking. (xvi ) This annex is only to be filed with the competent authority. (xvii) Whenever another person makes the notification on behalf of the shareholder or the natural person/legal entity referred to in DTR5.2 and DTR5.3 Schedule FIL Issuer name: Sinclair Pharma plc Current ownership percentage: 10.1% Total Shares Held: 9,352,556 Issued Share Capital: 93,361,219 +-------------------------------------------------------------------+ | Shares held | Nominee | Management Company | |-------------+--------------------------------+--------------------| | 88,175 | STATE STR BK AND TR CO LNDN (S | FPM | |-------------+--------------------------------+--------------------| | 153,123 | STATE STR BK AND TR CO LNDN (S | FIL | |-------------+--------------------------------+--------------------| | 322,214 | NORTHERN TRUST LONDON | FPM | |-------------+--------------------------------+--------------------| | 233,000 | JP MORGAN, BOURNEMOUTH | FPM | |-------------+--------------------------------+--------------------| | 2,506,738 | JP MORGAN, BOURNEMOUTH | FISL | |-------------+--------------------------------+--------------------| | 317,264 | JP MORGAN, BOURNEMOUTH | FIL | |-------------+--------------------------------+--------------------| | 272,661 | BROWN BROTHERS HARRIMAN AND CO | FIJ | |-------------+--------------------------------+--------------------| | 5,277,005 | BROWN BROS HARRIMN LTD LUX | FIL | |-------------+--------------------------------+--------------------| | 182,376 | BANK OF NEW YORK BRUSSELS | FPM | +-------------------------------------------------------------------+ ---END OF MESSAGE---